How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Glucagon Drug Market
- By Product Type: Glucagon Emergency Kits, Glucagon Injection Solutions, Nasal Glucagon Powder, Glucagon Auto-Injectors, Recombinant Glucagon
- By Route of Administration: Intramuscular Injection, Subcutaneous Injection, Nasal Spray
- By Indication: Severe Hypoglycemia Treatment, Diagnostic Aid in Radiology, Gastrointestinal Motility Disorders
- By End User: Hospitals, Home Care Settings, Ambulatory Care Centers, Pharmacies
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Glucagon Emergency Kits leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Glucagon Drug Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Route of Administration 3
Indication 3
End User 4
Distribution Channel 4
Companies profiled
Eli Lilly and Company
Novo Nordisk A/S
Sanofi S.A.
Xeris Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc.
Adocia
MannKind Corporation
Zosano Pharma Corporation
Locemia Solutions
Antares Pharma Inc.
Boehringer Ingelheim GmbH
Mylan N.V. (now part of Viatris)
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novo Nordisk A/S
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Xeris Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Amneal Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Adocia
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →MannKind Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Zosano Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Locemia Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Antares Pharma Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Boehringer Ingelheim GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Mylan N.V. (now part of Viatris)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,428M by 2033 · 11.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Glucagon Emergency Kits39.4
- Glucagon Injection Solutions20.9
- Nasal Glucagon Powder8.8
- Glucagon Auto-Injectors18.3
- Recombinant Glucagon12.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$747.1M → $1,941M · 12.7%
Europe$520.7M → $1,148M · 10.4%
Asia Pacific$475.4M → $1,217M · 12.5%
Latin America$294.3M → $785.3M · 13.1%
Middle East and Africa$226.4M → $506.5M · 10.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.502026
11.522027
11.522028
11.542029
11.552030
11.552031
11.582032
11.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Eli Lilly and Company24.3
- Novo Nordisk A/S9.1
- Sanofi S.A.13.2
- Xeris Pharmaceuticals Inc.9.3
- Amneal Pharmaceuticals Inc.10.9
- Adocia5.3
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type15.5%
Route of Administration24.9%
Indication19.9%
End User21.1%
Distribution Channel18.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe20.5
- Asia Pacific21.7
- Latin America14.0
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | 96 | 82 | 84 | 80 | 89 | 73 | 84 |
| Novo Nordisk A/S | 72 | 74 | 81 | 90 | 71 | 87 | 79 |
| Sanofi S.A. | 65 | 78 | 64 | 72 | 78 | 73 | 72 |
| Xeris Pharmaceuticals Inc. | 69 | 69 | 78 | 58 | 69 | 81 | 71 |
| Amneal Pharmaceuticals Inc. | 57 | 75 | 53 | 53 | 56 | 51 | 58 |
| Adocia | 61 | 46 | 71 | 64 | 54 | 65 | 60 |
| MannKind Corporation | 64 | 42 | 50 | 60 | 64 | 43 | 54 |
| Zosano Pharma Corporation | 57 | 47 | 35 | 54 | 51 | 38 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Eli Lilly and Company
- Novo Nordisk A/S
- Sanofi S.A.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Novo Nordisk A/S | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Sanofi S.A. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Xeris Pharmaceuticals Inc. | ◐ | − | ◐ | ◐ | − | ◐ |
| Amneal Pharmaceuticals Inc. | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Adocia | ◐ | − | ◐ | ◐ | − | ◐ |
| MannKind Corporation | − | ◐ | ◐ | − | ◐ | − |
| Zosano Pharma Corporation | ◐ | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eli Lilly and Company84
2Novo Nordisk A/S79
3Sanofi S.A.72
4Xeris Pharmaceuticals Inc.71
5Adocia60
6Amneal Pharmaceuticals Inc.58
7MannKind Corporation54
8Zosano Pharma Corporation47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Eli Lilly and CompanyNovo Nordisk A/S
Challenger2
Strong scale, closing on the leaders.
Sanofi S.A.Xeris Pharmaceuticals Inc.
Contender2
Focused players with pockets of strength.
Amneal Pharmaceuticals Inc.Adocia
Niche2
Specialists in a single segment or region.
MannKind CorporationZosano Pharma Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Glucagon Drug Market — a $243M beachhead inside a $4.29B market.
Beachhead (SOM)$243Mobtainable near-term
Serviceable (SAM)$1.49Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Glucagon Emergency Kits
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
Glucagon Injection Solutions
Strong fit — clear ROI and a fast path to value.
End user68 fit
Nasal Glucagon Powder
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Glucagon Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified22%
Evaluation14%
Closed-won6%
$15.3KCAC
$85KLTV
5.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Glucagon Drug Market is a durable-growth opportunity — $9.19B by 2033, compounding at 6.7%.
TAM · 2025$5.46Btoday
TAM · 2033$9.19Bforecast
CAGR6.7%2027–2033
Cumulative$64.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.19BTotal addressable market
SAM$3.84BServiceable available market
SOM$800MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.7% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.19BLarge & growingTAM by 2033 at 6.7% CAGR
$3.84BServiceable nowreachable with today’s model
$800MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.17BBear4.4% CAGR
$9.19BBase6.7% CAGR
$11.8BBull8.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Glucagon Drug Market — a $5.25B market by 2033. Plan: grow share from 8.7% to 16.6%.
Market size · 2033$5.25Btotal addressable
Market CAGR4.5%2027–2033
Target share16.6%from 8.7% today
Revenue ambition$871Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.7% | 16.6% | Behind |
| Revenue | $448M | $871M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.9% | 40.7% | Behind |
| Customer retention | 90.9% | 93.2% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $88M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Glucagon Drug Market conversation — a $5.33B market you can size, segment and defend in minutes.
Market size · 2033$5.33Btotal opportunity
Growth7.2%CAGR to 2033
Addressable buyers1,317+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 4 mopayback period
$64K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Eli Lilly and CompanyNovo Nordisk A/SSanofi S.A.Xeris Pharmaceuticals Inc.Amneal Pharmaceuticals Inc.AdociaMannKind CorporationZosano Pharma Corporation+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Glucagon Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Glucagon Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →GLP-1 Receptor Agonists Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportGLP-1R Agonist Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportGLP-1RA Drugs Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportGLP-1 for Weight Loss Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportGLP-1 for Diabetes Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportGLP-1 Analogues Market
GLP-1 Analogues Market is valued at USD 42 Billion in 2025 and is expected to reach USD 102.5 B…
$42.0B market · 2025 base year
View reportGLP-1 Agonist Market
GLP-1 Agonist Market is valued at USD 52 Billion in 2025 and is expected to reach USD 175 Billi…
$52.0B market · 2025 base year
View reportChemiluminescence Immunoassay Devices Market
Market size, share, segmentation and regional forecast.
$458M market · 2025 base year
View report2,3,5-Triiodo Benzoic Acid Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportGlow Cell Assay Reagents Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportLaboratory Sterilizer Market
Market size, share, segmentation and regional forecast.
$982M market · 2025 base year
View reportGlove Box Isolator Market
Market size, share, segmentation and regional forecast.
$543M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.